Fund Update: New $93.1M $CXT stock position opened by DEPRINCE RACE & ZOLLO INC
DEPRINCE RACE & ZOLLO INC opened a $93.1M position in CXT, according to a recent SEC 13F filing. 179 institutional investors increased their CXT holdings, while 201 decreased theirs in Q2 2026. Notable moves include additions by BLACKROCK and INVESCO, and removals by WELLINGTON MANAGEMENT and CAPITAL INTERNATIONAL.
How this was made

The 30-second read
Why it matters
The disclosed stake may attract other investors and increase liquidity for CXT.
Market read
Fresh 13F data provides actionable insight into institutional sentiment toward CXT.
What to watch
Potential upcoming clinical data or regulatory events for CXT not disclosed.
Background
13F filings reveal institutional holdings; new large positions can influence market perception.
Ticker impact
DEPRINCE RACE & ZOLLO INC disclosed a new $93.1M long position in CXT via its Q2 2026 13F filing.
Potential modest upside as the market absorbs the new demand.
The filing is the first public disclosure of a sizable $93M stake, indicating fresh interest from a hedge fund.
Market effects
May highlight growing interest in the biotech/health‑care sector.
Limited to US equity markets where CXT trades.
Low; primarily affects investors tracking CXT.
Counterpoint
The stake could be a short‑term tactical move; price may not sustain.
Key entities
- Hedge FundDEPRINCE RACE & ZOLLO INC
Institutional investor filing a 13F.
- CompanyCXT
Publicly traded company receiving a $93M stake.


